Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of QY101 Ointment in Healthy Chinese Subjects
NCT05429177Phase 1Completed
- Sponsor
- E-nitiate
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QY101 in atopic dermatitis (AD) and plaque psoriasis (10 cohorts), sponsored by E-nitiate. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Number of Participants With Clinical Laboratory Abnormalities at Day 11 and 4 more. Started Jun 2022; status: completed.
02
Drugs
QY101
03
Conditions
atopic dermatitis (AD)plaque psoriasis
Beyond the preview
Go deeper on NCT05429177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429177.